Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report

Ze-Long Liu,Xin Liu,Hong Peng,Zhen-Wei Peng,Jian-Ting Long,Di Tang,Sui Peng,Yong Bao,Ming Kuang

DOI: https://doi.org/10.3389/fmed.2020.00368

IF: 3.9

2020-08-28

Frontiers in Medicine

Abstract:Due to the unsatisfactory robustness of current predictive biomarkers in many cases, application of immunotherapy in advanced cancers with limited treatment options, such as stage IV intrahepatic cholangiocarcinoma (ICC), was quite common. Hence, strategies to enhance the therapeutic effect of immunotherapy or to extend the scope of potential beneficial patients were urgently needed. Combination of radiotherapy and anti-programmed death receptor-1 (PD-1) immunotherapy was a promising one, since they were found to have a synergistic anti-tumor effect in animal models and a couple of patients. We here present a 68-years-old male with chemotherapy-intolerable stage IV ICC, whose primary tumor had low PD-L1 expression level, scarce CD8+ cells in tumor microenvironment, high microsatellite instability (MSI), and high tumor mutation burden (TMB). These biomarkers showed a conflicting prediction of the treatment response and clinical benefit of anti-PD-1 immunotherapy. Combination therapy of anti-PD-1 immunotherapy and radiotherapy was adopted as first-line treatment for the patient. After six cycles of immunotherapy, shrinkage of the primary liver tumor and metastatic lymph nodes happened, alongside with new lung metastasis, which indicated a mixed response. Radiotherapy was then administered to both the liver and lung lesions, accompanied with continued immunotherapy. The combined therapy eventually led to a complete response for both the primary tumor and all metastases without treatment-related adverse effects. The patient has survived for 26 months after the combined therapy and remains tumor-free currently. This case demonstrates the high inconsistency between immunotherapy response biomarkers and the synergetic anti-tumor effect of immunotherapy and radiotherapy in ICC.

medicine, general & internal

What problem does this paper attempt to address?

This paper aims to solve several key problems in the treatment of advanced intrahepatic cholangiocarcinoma (ICC):

1. **Limited treatment options**: For patients with advanced ICC, the current chemotherapy regimens are ineffective and have severe side effects, causing many patients to be unable to tolerate them. Therefore, there is an urgent need to find new and effective treatment strategies.

2. **Inconsistency of predictive markers for immunotherapy response**: Although some biomarkers such as PD - L1 expression level, microsatellite instability (MSI), tumor mutation burden (TMB), etc. are used to predict the response to immunotherapy, the accuracy of these markers in different tumor types is limited, and in some cases they are contradictory.

3. **Effectiveness of combined application of immunotherapy and radiotherapy**: The study explored the potential synergistic anti - tumor effect of the combination of immune checkpoint inhibitors (such as anti - PD - 1 antibody) and radiotherapy, especially in those patients with poor efficacy of traditional treatment methods.

Specifically, through the case of a 68 - year - old male patient, the paper shows that in a stage IV ICC patient who is intolerant to chemotherapy, there are conflicting prediction results of biomarkers such as low PD - L1 expression, scarce CD8+ cells in the tumor microenvironment, high MSI and high TMB. Nevertheless, after receiving the combined treatment of anti - PD - 1 immunotherapy and radiotherapy, this patient achieved complete remission, and the quality of life was significantly improved, and the survival time was extended to 26 months.

This case study indicates that even in the case of inconsistent biomarker prediction results, the combined use of immunotherapy and radiotherapy may still bring significant clinical benefits to patients with advanced ICC. This provides an important reference for future research and clinical practice.